PROK vs. NAMS, IDYA, SDGR, TVTX, BLTE, VERA, IOVA, PRAX, GLPG, and WVE
Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
ProKidney vs.
NewAmsterdam Pharma (NASDAQ:NAMS) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
NewAmsterdam Pharma received 16 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 57.14% of users gave ProKidney an outperform vote.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 19.5% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
NewAmsterdam Pharma presently has a consensus target price of $41.60, suggesting a potential upside of 124.02%. ProKidney has a consensus target price of $4.50, suggesting a potential upside of 200.00%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than NewAmsterdam Pharma.
ProKidney has lower revenue, but higher earnings than NewAmsterdam Pharma.
NewAmsterdam Pharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
In the previous week, NewAmsterdam Pharma had 4 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 0 mentions for ProKidney. NewAmsterdam Pharma's average media sentiment score of 0.71 beat ProKidney's score of 0.00 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
Summary
NewAmsterdam Pharma beats ProKidney on 9 of the 13 factors compared between the two stocks.
Get ProKidney News Delivered to You Automatically
Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProKidney Competitors List
Related Companies and Tools
This page (NASDAQ:PROK) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PROK Stock Alerts